Sentences with phrase «price action over»

Price action over the past five days...

The media has been talking a lot about the explosive price action over the past year, but they're not doing a great job at educating people how all of it works and what amazing innovations are being created.

However, price action over the past 24 hours has been highly volatile, with volumes exceeding $ 200 million, according to CoinMarketCap.

Technical analysis show that the price action over the last month has created a reversal pattern that can take Bitcoin Cash to 0.43.

Price action over the past five days signals a clear shift upward for the world's largest cryptocurrency.

Bitcoin and other cryptocurrency have been stagnant with very little price action over the last month.

Price action over the past two days seems to corroborate the view that the world's first virtual currency could be headed for a correction.

The FRAMA is a type of Adaptive Moving Average that deploys fractal geometry to dynamically fine - tune its smoothing period to fit the altering price action over a given time.

If you have been studying price action over the last year but you just don't feel as confident with as you want to, take your knowledge of it to the next level by getting a comprehensive price action trading education.

Last time there was volatile price action over Thursday and Friday as the BoE decided policy, released data, and announced their decisions and rationale.

Price action over the last four days can be seen as a â $ ˜ pennantâ $ ™ suggesting another burst higher this week with a measured target of at least 1.4720, maybe 1.4825.

The chart above shows how the current 61.8 Fibonacci level has impacted price action over the last several years.

I have written many articles on why I prefer price action over any other method, but in case you missed them, are a few for you to check out:

In order for either Ethereum or Ripple to catch up and surpass BTC, it would take an extreme amount of price action over a lengthy period of time.

Go back and look at price action over the past two weeks and see if you can determine if support and resistance levels the past two to three days can be verified.

However, the tight price action over the next seven days was bullish, and allowed us to increase our exposure with a second low - risk entry point on August 24:

Price action over the past five days...

The iShares MSCI Singapore Index Fund ($ EWS) has been exhibiting tight, sideways price action over the past six weeks, near its prior highs and just above the $ 13.50 level.

Based on the price action over the course of the past several months, the most likely scenario is a continuation of lower prices.

We will possibly analyze $ QQQ in our technical ETF commentary later this week, depending on its price action over the next few days.

The iShares MSCI Singapore Index Fund ($ EWS) has been exhibiting tight, sideways price action over the past six weeks, near its prior highs and just above the $ 13.50 -LSB-...]

Oil Refiners and Homebuilders are two examples of industry sectors with disappointing price action over the past two weeks.

By viewing a series of stock price actions over a period of time (intraday), you'll be in a better position to predict how they're going to behave in future.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

In particular, agriculture states, already battered by low crop prices and poor weather, are antsy about getting slammed by tariffs in retaliation for Trump trade actions over steel, aluminum and China.

NEW YORK / LONDON, April 13 - Gold prices rose on Friday, heading for a second consecutive weekly gain on lingering uncertainty over Western military action in Syria.

As for deflation, the «unprecedented policy actions» from central banks around the world means falling prices are unlikely over the next several years.

BI: What pieces of new information (e.g. economic data releases, price action in a given market over the next few days / weeks, etc.) do you think have the biggest potential to alter your outlook?

CNBC's Jackie DeAngelis reports on the trading action in crude, as oil prices slide on global growth worries over demand.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

NEW YORK, April 11 (Reuters)- Oil prices jumped on Wednesday, hitting their highest in more than three years on Wednesday after Saudi Arabia said it intercepted missiles over Riyadh and U.S. President Donald Trump warned Russia of imminent military action in Syria.

The price action in Zcash over the last four or so months is another example of just how sophisticated investors truly are and why all theories in crypto investment bubbles need to be permanently discarded.

Based on yesterday's (May 23) bullish intraday price action, in which stocks shook off substantial early losses and reversed to finish flat to higher on increasing volume, it appears as if we will see a move higher in the main stock market indexes over the next several days.

When that sideways price action occurs on substantially decreasing volume it is usually a sign that the current pullback may be over and that the uptrend is ready to resume.

Over the past few weeks, price action has been quiet and volatility has been low, with the price trading in a tight range near the highs of the base:

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

On the weekly chart above, notice the tight price action near resistance of the 40 - week moving average (similar to 200 - day moving average) over the preceding four weeks.

My definition of Price Action Analysis: Price action analysis is the analysis of the price movement of a market over Price Action Analysis: Price action analysis is the analysis of the price movement of a market overAction Analysis: Price action analysis is the analysis of the price movement of a market over Price action analysis is the analysis of the price movement of a market overaction analysis is the analysis of the price movement of a market over price movement of a market over time.

As anticipated, price action followed through to the upside over the next few days, and quickly cleared the high of the wide - ranged reversal candle from March 12.

To learn more about how I have incorporated money management and price action entry signals to grow my account over the long term, checkout my Price Action Trading Course and Members Area for price action entry signals to grow my account over the long term, checkout my Price Action Trading Course and Members Area foraction entry signals to grow my account over the long term, checkout my Price Action Trading Course and Members Area for Price Action Trading Course and Members Area forAction Trading Course and Members Area for more.

The reality is this sort of price action is something that Apple shareholders have grown very accustomed to over the last few years.

I want to go over a few charts of real - world recent examples of price action trade setups.

Accordingly, price action frequently becomes quite volatile, with multiple crosses above and below the 20 - EMA over the next few days.

The latest price action in USD - CAD has negated the downside trend that had been in play over the prior three weeks, from levels near 1.3100.

Because of the current pullback to the 10 - week MA, we expect the price action to hold at or around this level over the next week or two before the uptrend resumes.

Over the past few weeks, we have stated several times that paying attention to the price action of leading stocks and industry sectors is best way to gauge the health of the market.

Over the coming weeks and months, several things are probably going to happen that could serve to bolster the bulls even more so than the price action alone has already.

In the event of a change of control (as defined in the plan), the compensation committee may, in its discretion, provide for any or all of the following actions: (i) awards may be continued, assumed, or substituted with new rights, (ii) awards may be purchased for cash equal to the excess (if any) of the highest price per share of common stock paid in the change in control transaction over the aggregate exercise price of such awards, (iii) outstanding and unexercised stock options and stock appreciation rights may be terminated, prior to the change in control (in which case holders of such unvested awards would be given notice and the opportunity to exercise such awards), or (iv) vesting or lapse of restrictions may be accelerated.

Feeling bullish over the latest Bitcoin price action?

trade regulations and procedures and actions affecting production, pricing and marketing of products, including policies adopted by countries that may champion or otherwise favor domestic companies and technologies over foreign competitors;